A Novel Microfluidic Platform for Circulating Tumor Cell Identification in Non-Small-Cell Lung Cancer

Area of Science:

• Biomedical Engineering
• Oncology
• Microfluidics

Background:

• Circulating tumor cells (CTCs) are vital biomarkers for lung cancer metastasis and recurrence.
• Current CTC detection methods lack efficiency and cost-effectiveness, hindering clinical application.
• There is a critical need for sensitive CTC detection technologies for improved lung cancer diagnosis and treatment.

Purpose of the Study:

• To develop and evaluate acoustic microfluidic technology for efficient CTC capture.
• To assess the impact of acoustic forces on cell viability and proliferation.
• To integrate CTC capture with EGFR mutation analysis for personalized lung cancer therapy.

Main Methods:

• Utilized microspheres and A549 cells to model CTCs, assessing acoustic field forces.
• Captured CTCs from lung cancer patients' blood using acoustic microfluidics.
• Compared fluorescence in situ hybridization with immunomagnetic bead methods for CTC identification.
• Performed epidermal growth factor receptor (EGFR) mutation analysis on captured CTCs.

Main Results:

• Acoustic microfluidic technology demonstrated effective capture of microspheres, A549 cells, and patient CTCs.
• Cell viability and proliferation were maintained during the acoustic capture process.
• EGFR mutation analysis successfully identified mutation types in four CTC-positive samples.
• The developed method showed promise for personalized targeted therapy.

Conclusions:

• Acoustic microfluidic technology offers a viable solution for efficient CTC capture while preserving cell integrity.
• Integration with EGFR mutation analysis provides a powerful tool for precise lung cancer diagnosis and treatment.
• This approach supports the development of personalized drug therapies for lung cancer patients.